Is a wholly owned subsidiary of Eisai Corporation of North America.

The company serves as the U.S. Pharmaceutical operation of Eisai Co. , a research-based human health care company. Discovers, develops and markets products throughout the world Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. Has. More R & D in Massachusetts, New Jersey and North Carolina, as well as manufacturing facilities in Maryland and North Carolina.. Eisai Inc. Is a wholly owned subsidiary of Eisai Corporation of North America.Was founded in 1995 and among the top-20 U.S. Pharmaceutical companies ranked , the company began marketing its first product in the United States in 1997 and has rapidly grown to a fully integrated pharmaceutical business become with the 2008 fiscal year revenue of about 7 billion.

CONTACT: Michael Bernstein ACS News Service###The American Chemical Society – the world’s largest scientific society – is a nonprofit organization supported by Congress chartered the United States and a global leader in providing access to chemistry – research through its multiple databases, journals and peer-reviewed scientific conferences. Its headquarters are in Washington, DC , and Columbus.4SC AG , a drug discovery and development of , today announced to to the at in the, phase I TOPAS trial with 4SC-202 is a selective a histone deacetylase inhibitor that anti an anti-mitotic mechanism of. That study will safety, pharmacokinetics and clinical activity of orally administered 4SC-202 into patients with advanced hematologic indications, including acute myeloid leukemia , acute lymphocytic leukemia , chronic lymphocytic leukemia , multiple myeloma , myelodysplastic syndrome and lymphomas. In this second HDAC inhibitor by 4SC ‘s lead oncology business in addition, a pan – HDAC inhibitor.

Anti-tumor 4SC-202 tablets once a day 14 consecutive days of a 21-day cycle of . , The main phase of the study are benefiting from two cycles of treatment and the end at the end the main course stage the therapeutic in a subsequent follow-up stage consisting stay. Gradual escalation of the starting dose is arise after a standard 3+3 design. Each dosage cohort will be. Up to 6 patients and that trial is currently planning to registered post overall 36 patients The observed according to the pharmacokinetic profile and tolerability of once-daily dosing of 4SC-202, Alternatively dose regimens how administered twice daily is to be parsed..